New Horizons: Finally, Approaches to Treating Moderate to Severe Atopic Dermatitis
Allergy/ Immunology
Curriculum:
A Self-Assessment Program on Managing Atopic Dermatitis and Improving Patient Outcomes
A Self-Assessment Program on Managing Atopic Dermatitis and Improving Patient Outcomes
Credits:
1 AMA PRA Category 1 Credit(s) ™
1 AMA PRA Category 1 Credit(s) ™
Launch Date:
October 24, 2017
October 24, 2017
Expiration Date:
The accreditation for this activity has expired.
The accreditation for this activity has expired.
Primary Audience:
Physicians, nurse practitioners, and physician assistants who specialize in allergy/immunology and dermatology
Relevant Terms:
Atopic Dermatitis (AD)
Jonathan Silverberg, MD, PhD, MPH
Jonathan Silverberg, MD, PhD, MPH
Assistant Professor, Dermatology, Preventive Medicine, and Medical Social Sciences
Northwestern University Feinberg School of Medicine
Director, Northwestern Medicine
Multidisciplinary Eczema Center
Director, Patch Testing Clinic
Northwestern Memorial Hospital
Chicago, IL
Bio
Jonathan Silverberg, MD, PhD, MPH, is an assistant professor in the Departments of Dermatology, Preventive Medicine, and Medical Social Sciences at Northwestern University Feinberg School of Medicine in Chicago, Illinois. Dr Silverberg is the director of the Northwestern Medicine Multidisciplinary Eczema Center and founded the Multidisciplinary Eczema Clinic at Northwestern Medicine. He is also the director of the contact dermatitis clinic and photobiologic testing at Northwestern Memorial Hospital, which provides comprehensive evaluation and management of skin allergies and photosensitivity. He was the recipient of the Georg Rajka Medal from the International Society of Atopic Dermatitis, the Teacher of the Year Award in the Department of Dermatology at Northwestern Memorial Hospital, and the Everett C. Fox Research Award from the American Academy of Dermatology.
Dr Silverberg completed both his medical degree and master of public health degree in 2009 at State University of New York, Downstate Medical Center in Brooklyn, New York. His master's thesis focused on the protective role of herpesviridae on atopic dermatitis and other allergic disorders as part of the broader "hygiene hypothesis." He completed his doctorate in 2006 with thesis studies in neuroimmunology focused on murine immune responses after a seizure. He performed his residency training at St. Luke's-Roosevelt Hospital Center at Columbia University in New York City, New York.
His research goals are to better understand the risk factors and medical comorbidities of atopic dermatitis in the U.S. population. Dr Silverberg has authored 141 scientific articles and book chapters, including studies of the epidemiology of atopic dermatitis and "big data" research. He has extensive experience with database development, instrument development and deployment, and statistical programming.
Dr Silverberg is an associate editor for the British Journal of Dermatology and Current Dermatology Reports and is on the editorial board of Cutis. He is a member of the National Eczema Association Scientific Advisory Committee and American Academy of Dermatology Atopic Dermatitis Expert Resource Group, and he is chair of the Society of Investigative Dermatology Atopic Dermatitis Epidemiology Working Group. He is also a member of the Alpha Omega Alpha honor society, American Academy of Dermatology, Society of Investigative Dermatology, American Contact Dermatitis Society, Illinois Dermatologic Society, and Chicago Dermatologic Society.
Dr Silverberg completed both his medical degree and master of public health degree in 2009 at State University of New York, Downstate Medical Center in Brooklyn, New York. His master's thesis focused on the protective role of herpesviridae on atopic dermatitis and other allergic disorders as part of the broader "hygiene hypothesis." He completed his doctorate in 2006 with thesis studies in neuroimmunology focused on murine immune responses after a seizure. He performed his residency training at St. Luke's-Roosevelt Hospital Center at Columbia University in New York City, New York.
His research goals are to better understand the risk factors and medical comorbidities of atopic dermatitis in the U.S. population. Dr Silverberg has authored 141 scientific articles and book chapters, including studies of the epidemiology of atopic dermatitis and "big data" research. He has extensive experience with database development, instrument development and deployment, and statistical programming.
Dr Silverberg is an associate editor for the British Journal of Dermatology and Current Dermatology Reports and is on the editorial board of Cutis. He is a member of the National Eczema Association Scientific Advisory Committee and American Academy of Dermatology Atopic Dermatitis Expert Resource Group, and he is chair of the Society of Investigative Dermatology Atopic Dermatitis Epidemiology Working Group. He is also a member of the Alpha Omega Alpha honor society, American Academy of Dermatology, Society of Investigative Dermatology, American Contact Dermatitis Society, Illinois Dermatologic Society, and Chicago Dermatologic Society.
| 1. | Describe the pathogenesis of atopic dermatitis (AD) and the "atopic march" and discuss how the underlying pathology of the disease can be used to direct therapy | 2. | Utilize current therapies and describe how to utilize emerging treatments for AD based on safety and efficacy data, pathophysiology, guidelines, individual patient needs, and sustained efficacy, especially in patients with moderate to severe AD |
| 3. | Manage quality-of-life issues, psychosocial comorbidities, and treatment-related anxiety in patients with AD | 4. | Engage the patient as a partner in his or her care plan to ensure best treatment adherence and outcomes |
| 1. | Describe the pathogenesis of atopic dermatitis (AD) and the "atopic march" and discuss how the underlying pathology of the disease can be used to direct therapy |
| 2. | Utilize current therapies and describe how to utilize emerging treatments for AD based on safety and efficacy data, pathophysiology, guidelines, individual patient needs, and sustained efficacy, especially in patients with moderate to severe AD |
| 3. | Manage quality-of-life issues, psychosocial comorbidities, and treatment-related anxiety in patients with AD |
| 4. | Engage the patient as a partner in his or her care plan to ensure best treatment adherence and outcomes |
Physician Continuing Medical Education
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Postgraduate Institute for Medicine and RMEI Medical Education, LLC. The Postgraduate Institute for Medicine is accredited by the ACCME to provide continuing medical education for physicians.
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 1 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Postgraduate Institute for Medicine and RMEI Medical Education, LLC. The Postgraduate Institute for Medicine is accredited by the ACCME to provide continuing medical education for physicians.
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 1 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Disclosure of Conflicts of Interest
Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high-quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.
The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:
The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:
- Jonathan Silverberg, MD, PhD, MPH, has affiliations with AbbVie, Anacor, Eli Lilly, GlaxoSmithKline (GSK), MedImmune, Procter & Gamble, Pfizer, PuriCore, and Regeneron-Sanofi (Consulting Fees); and AbbVie, Celgene, Eli Lilly, GSK, Regeneron-Sanofi, and Roche (Investigator in Clinical Trials).
The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:
RMEI Medical Education, LLC
- Jacqui Brooks, MBBCh, MRCPsych, has no affiliations with commercial interests to disclose.
- Chelsey Goins, PhD, has no affiliations with commercial interests to disclose.
Planners and Managers
The PIM planners and managers, Trace Hutchison, PharmD; Samantha Mattiucci, PharmD, CHCP; Judi Smelker-Mitchek, MBA, MSN, RN; and Jan Schultz, MSN, RN, CHCP, have nothing to disclose.
The PIM planners and managers, Trace Hutchison, PharmD; Samantha Mattiucci, PharmD, CHCP; Judi Smelker-Mitchek, MBA, MSN, RN; and Jan Schultz, MSN, RN, CHCP, have nothing to disclose.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients' conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Estimated Time to Complete: 1 hour
Media
Internet
Fee Information
There is no fee for this educational activity.
There is no fee for this educational activity.
Statement of Commercial Support
This activity is jointly provided by RMEI Medical Education, LLC and Postgraduate Institute for Medicine. This activity is supported by an independent educational grant from Genzyme, a Sanofi Company, and Regeneron Pharmaceuticals.
How to Receive Credit
By reviewing the course content and successfully completing the post-test and evaluation, physicians, nurse practitioners, and physician assistants are entitled to receive up to 1 AMA PRA Category 1 Credit(s)™. A statement of credit will be available to print from your user history page. Users must:
- Read the learning objectives and faculty disclosures.
- Participate in the activity.
- Complete the activity evaluation.
Physicians, nurse practitioners, and physician assistants who successfully complete the post-test and evaluation will receive CME credit. You must score 75% or higher on the post-test to receive credit for this activity. All other participants who successfully complete the post-test and evaluation will receive a certificate of participation.
COURSE VIEWING REQUIREMENTS
| Supported Browsers: Internet Explorer 8.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1 and above Google Chrome 28.0+ for Windows, Mac OS, or Linux Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux Safari 6.0+ for Mac OSX 10.7 and above | Supported Phones & Tablets: Android 4.0.3 and above iPhone/iPad with iOS 6.1 or above. |
© 2007-2024 HealthCourse, Inc. All rights reserved.
